Absci (ABSI) Change in Receivables (2024 - 2025)
Absci (ABSI) posted Change in Receivables of -$1.0 million for Q4 2025, down 433.33% sequentially from $300000.0 in Q3 2025, and up 33.33% YoY from -$750000.0 in Q4 2024.
Powered by 
Analysis
Absci (ABSI) Change in Receivables (2024 - 2025) Analysis & Trends
Absci has reported Change in Receivables for 2 years, with the latest figure at -$1.0 million in Q4 2025.
- Quarterly Change in Receivables rose 33.33% year-over-year to -$1.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$1.4 million (down 207.12% YoY) and the FY2024 annual result came in at -$2.2 million, down 436.19% from the prior year.
- Change in Receivables eased to -$1.0 million in Q4 2025 per ABSI's latest filing, from $300000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $1.4 million in Q3 2024 and troughed at -$2.1 million in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -1.00 Mn |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | -684,000.00 |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | -1.50 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | -2.15 Mn |